<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36420234</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Demonstrates That Inflammation Is a Hyperviscous State.</ArticleTitle><Pagination><StartPage>e30603</StartPage><MedlinePgn>e30603</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e30603</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.30603</ELocationID><Abstract><AbstractText>Many of the complications of severe coronavirus disease-2019 (COVID-19) are caused by blood hyperviscosity driven by marked hyperfibrinogenemia. This results in a distinctive hyperviscosity syndrome which affects areas of high and low shear. A change in blood viscosity causes a threefold inverse change in blood flow, which&#xa0;increases the risk of thrombosis in both arteries and veins despite prophylactic anticoagulation. Increased blood viscosity decreases perfusion of all tissues, including the lungs, heart, and brain.&#xa0;Decreased perfusion of the lungs causes global ventilation-perfusion mismatch which results in silent hypoxemia and decreased efficacy of positive pressure ventilation in treating pulmonary failure in COVID-19. Increased blood viscosity causes a mismatch in&#xa0;oxygen supply and demand in the heart, resulting in myocarditis and ventricular diastolic dysfunction. Decreased perfusion of the brain causes demyelination because of a sublethal cell injury to oligodendrocytes. Hyperviscosity can cause stasis in capillaries, which can cause endothelial necrosis. This can lead to the rarefaction of capillary beds, which is noted in "long-COVID." The genome of the virus which causes COVID-19, severe acute respiratory syndrome coronavirus 2, contains an&#xa0;extraordinarily high number of the oligonucleotide virulence factor&#xa0;5'-purine-uridine-uridine-purine-uridine-3', which binds to toll-like receptor 8, hyperactivating innate immunity. This can lead&#xa0;to a marked elevation in fibrinogen levels and an increased&#xa0;prevalence of neutrophil extracellular traps in pulmonary failure, as seen in COVID-19 patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022, Sloop et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sloop</LastName><ForeName>Gregory D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Pathology, Idaho College of Osteopathic Medicine, Meridian, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pop</LastName><ForeName>Gheorghe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiology, Radboud University Medical Center, Nijmegen, NLD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weidman</LastName><ForeName>Joseph J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Internal Medicine, Independent Researcher, Columbia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St Cyr</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Cardiac/Thoracic/Vascular Surgery, Jacqmar, Inc., Minneapolis, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">blood viscosity</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">fibrinogen</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">myocarditis</Keyword><Keyword MajorTopicYN="N">sars-cov-2</Keyword><Keyword MajorTopicYN="N">silent hypoxemia</Keyword><Keyword MajorTopicYN="N">toll-like receptor 8</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>24</Day><Hour>2</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36420234</ArticleId><ArticleId IdType="pmc">PMC9680816</ArticleId><ArticleId IdType="doi">10.7759/cureus.30603</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The detrimental role of elevated blood viscosity in patients with COVID-19. Sloop GD, Pop GA, Weidman JJ, St. Cyr JA. http://www.ghrnet.org/index.php/jct/article/view/3181 J Cardiol Ther. 2021;8(1):976&#x2013;980.</Citation></Reference><Reference><Citation>Association of blood viscosity with mortality among patients hospitalized with COVID-19. Choi D, Waksman O, Shaik A, et al. J Am Coll Cardiol. 2022;80:316&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9291270</ArticleId><ArticleId IdType="pubmed">35863848</ArticleId></ArticleIdList></Reference><Reference><Citation>From the oligonucleotide purUUpurU to cytokine storm, elevated blood viscosity, and complications of coronavirus disease 2019. Sloop GD, Pop GA, Weidman JJ, Moraru L, St Cyr JA. Cureus. 2022;14:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9272904</ArticleId><ArticleId IdType="pubmed">35832759</ArticleId></ArticleIdList></Reference><Reference><Citation>Impact of COVID-19 on red blood cell rheology. Renoux C, Fort R, Nader E, et al. Br J Haematol. 2021;192:0&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">33410504</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood viscosity of COVID-19 patient: a preliminary report. Joob B, Wiwanitkit V. https://pubmed.ncbi.nlm.nih.gov/33796395/ Am J Blood Res. 2021;11:93&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010604</ArticleId><ArticleId IdType="pubmed">33796395</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood hyperviscosity in acute and recent COVID-19 infection. Shaik A, Chen Q, Mar P, et al. Clin Hemorheol Microcirc. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9741734</ArticleId><ArticleId IdType="pubmed">35466930</ArticleId></ArticleIdList></Reference><Reference><Citation>The systemic vascular resistance response: a cardiovascular response modulating blood viscosity with implications for primary hypertension and certain anemias. Sloop GD, Weidman JJ, St Cyr JA. Ther Adv Cardiovasc Dis. 2015;9:403&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">26116626</ArticleId></ArticleIdList></Reference><Reference><Citation>The role of blood viscosity in infectious diseases. Sloop GD, De Mast Q, Pop G, Weidman JJ, St Cyr JA. Cureus. 2020;12:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096068</ArticleId><ArticleId IdType="pubmed">32226691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, Lippi G. Am J Emerg Med. 2020;38:1722&#x2013;1726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251362</ArticleId><ArticleId IdType="pubmed">32738466</ArticleId></ArticleIdList></Reference><Reference><Citation>Significant dominance of fibrinogen over immunoglobulins, C-reactive protein, cholesterol and triglycerides in maintaining increased red blood cell adhesiveness/aggregation in the peripheral venous blood: a model in hypercholesterolaemic patients. Schechner V, Shapira I, Berliner S, et al. Eur J Clin Invest. 2003;33:955&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pubmed">14636298</ArticleId></ArticleIdList></Reference><Reference><Citation>Local RBC aggregation disturbing blood fluidity and causing stasis in microvessels. McHedlishvili G, Varazashvili M, Gobejishvili L. https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch487. Clin Hemorheol Microcirc. 2002;26:99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">12082258</ArticleId></ArticleIdList></Reference><Reference><Citation>Registry of arterial and venous thromboembolic complications in patients with COVID-19. Piazza G, Campia U, Hurwitz S, et al. J Am Coll Cardiol. 2020;76:2060&#x2013;2072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7588178</ArticleId><ArticleId IdType="pubmed">33121712</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? Maier CL, Truong AD, Auld SC, Polly DM, Tanksley CL, Duncan A. Lancet. 2020;395:1758&#x2013;1759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7247793</ArticleId><ArticleId IdType="pubmed">32464112</ArticleId></ArticleIdList></Reference><Reference><Citation>Device-related thrombus overlying a left-atrial occlusion device implanted for persistent spontaneous echo contrast despite prolonged oral anticoagulation therapy. Elabbassi W, Osman AN, Chowdhury MA, Nooryani AA. Cardiology. 2013;125:78&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">23689797</ArticleId></ArticleIdList></Reference><Reference><Citation>The clinical signi&#xfb01;cance of whole blood viscosity in (cardio)vascular medicine. Pop GAM, Duncker DJ, Gardien M, Vranckx P, Versluis S, Hasan DM, Slager C. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2499821/ Neth Heart J. 2002;10:512&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2499821</ArticleId><ArticleId IdType="pubmed">25696056</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH ACTIV trial of blood thinners pauses enrollment of critically ill COVID-19 patients. 2020. https://www.nhlbi.nih.gov/news/2020/nih-activ-trial-blood-thinners-pauses-enrollment-critically-ill-covid-19-patients https://www.nhlbi.nih.gov/news/2020/nih-activ-trial-blood-thinners-pauses-enrollment-critically-ill-covid-19-patients</Citation></Reference><Reference><Citation>Blood viscosity as a forgotten factor and its effect on pulmonary flow. Cakmak G, Alkan FA, Korkmaz K, Saglam ZA, Karis D, Yenigun M, Ercan M. Transl Respir Med. 2013;1:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6733503</ArticleId><ArticleId IdType="pubmed">27234385</ArticleId></ArticleIdList></Reference><Reference><Citation>Early detection of silent hypoxia in Covid-19 pneumonia using smartphone pulse oximetry. Teo J. J Med Syst. 2020;44:134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305055</ArticleId><ArticleId IdType="pubmed">32562006</ArticleId></ArticleIdList></Reference><Reference><Citation>Silent hypoxia: a harbinger of clinical deterioration in patients with COVID-19. Wilkerson RG, Adler JD, Shah NG, Brown R. Am J Emerg Med. 2020;38:2243&#x2013;2246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243756</ArticleId><ArticleId IdType="pubmed">32471783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechanism of stimulation of type J pulmonary receptors. Paintal AS. J Physiol. 1969;203:511&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1351528</ArticleId><ArticleId IdType="pubmed">5387024</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. Ackermann M, Verleden SE, Kuehnel M, et al. N Engl J Med. 2020;383:120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>TLR7/8 activation in neutrophils impairs immune complex phagocytosis through shedding of FcgRIIA. Lood C, Arve S, Ledbetter J, Elkon KB. J Exp Med. 2017;214:2103&#x2013;2119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5502427</ArticleId><ArticleId IdType="pubmed">28606989</ArticleId></ArticleIdList></Reference><Reference><Citation>Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Middleton EA, He XY, Denorme F, et al. Blood. 2020;136:1169&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472714</ArticleId><ArticleId IdType="pubmed">32597954</ArticleId></ArticleIdList></Reference><Reference><Citation>From neutrophil extracellular traps release to thrombosis: an overshooting host-defense mechanism? Borissoff JI, ten Cate H. J Thromb Haemost. 2011;9:1791&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pubmed">21718435</ArticleId></ArticleIdList></Reference><Reference><Citation>Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study. Szekely Y, Lichter Y, Taieb P, et al. Circulation. 2020;142:342&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382541</ArticleId><ArticleId IdType="pubmed">32469253</ArticleId></ArticleIdList></Reference><Reference><Citation>Myocarditis and thrombosis following immunization for COVID19 are caused by elevated blood viscosity and may be prevented by optimal oral hydration. Sloop GD, Pop G, Weidman JJ, St. Cyr JA. https://www.researchgate.net/publication/356775172_Myocarditis_and_Thrombosis_Following_Immunization_for_COVID-19_Are_Caused_By_Elevated_Blood_Viscosity_and_May_Be_Prevented_By_Optimal_Oral_Hydration J Card Cardiovasc Res. 2021;3:1&#x2013;4.</Citation></Reference><Reference><Citation>Nervous system involvement in coronavirus disease 2019: results from a retrospective consecutive neuroimaging cohort. Klironomos S, Tzortzakakis A, Kits A, et al. Radiology. 2020;297:0&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7393954</ArticleId><ArticleId IdType="pubmed">32729812</ArticleId></ArticleIdList></Reference><Reference><Citation>Oligodendrogliopathy in multiple sclerosis: low glycolytic metabolic rate promotes oligodendrocyte survival . Rone MB, Cui Q-L, Fang J, et al. J. Neurosci. 2016;36(17):4698&#x2013;4707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6601725</ArticleId><ArticleId IdType="pubmed">27122029</ArticleId></ArticleIdList></Reference><Reference><Citation>Persistent capillary rarefication in long COVID syndrome. Osiaevi I, Schulze A, Evers G, et al. Angiogenesis. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9366128</ArticleId><ArticleId IdType="pubmed">35951203</ArticleId></ArticleIdList></Reference><Reference><Citation>PurUUpurU: An oligonucleotide virulence factor in RNA viruses. Sohn WJ, Sloop GD, Pop G, Weidman J, St. Cyr JA. Cureus. 2022;14:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9581542</ArticleId><ArticleId IdType="pubmed">36284814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>